Market Place
Sourcing Support
Octapharma USA Gets FDA EUA For octaplasLG Powder For Military Use
20 Aug 2024 //
PR NEWSWIRE
FDA Approves New Indication For Fibryga®
01 Aug 2024 //
PR NEWSWIRE
Octapharma Showcases Rare Bleeding Disorders Commitment At ISTH 2024
10 Jun 2024 //
PR NEWSWIRE
Octapharma USA Appoints Kelly Hearn VP Commercial Marketing
20 May 2024 //
PR NEWSWIRE
Octapharma`s wilate® Gets FDA Orphan Exclusivity for VWD Prophylaxis
29 Apr 2024 //
PR NEWSWIRE
Publication of data from WIL-31 study marks a milestone
22 Jan 2024 //
PR NEWSWIRE
Octapharma to present data that advances treatment of bleeding disorders
17 Jan 2024 //
PR NEWSWIRE
Octapharma Announces Availability of Balfaxar® For Warfarin Reversal
03 Jan 2024 //
PR NEWSWIRE
Octapharma USA: FDA Grants Expanded Approval to wilate
05 Dec 2023 //
PR NEWSWIRE
Octapharma secures FDA nod for warfarin reversal agent Balfaxar
26 Jul 2023 //
FIERCE PHARMA
Octapharma Puts a Spotlight on Infection Burden in CLL at EHA Congress 2023
07 Jun 2023 //
BUSINESSWIRE
Octapharma presents data at ISTH in an commitment to improve bleeding disorders
06 Jun 2023 //
PR NEWSWIRE
Octapharma presents data at ISTH in commitment to improve bleeding disorders
06 Jun 2023 //
PR NEWSWIRE
Octapharma USA Requests FDA Approval for wilate® VWD Prophylaxis Supplement
23 Feb 2023 //
PR NEWSWIRE
Octapharma to put the perspectives of patients under the spotlight at EAHAD
18 Jan 2023 //
PR NEWSWIRE
Octapharma to present new clinical data and studies at ASH 2022
05 Dec 2022 //
PRNEWSWIRE
ProDERM Study Results of octagam 10% Treatment in Patients Published in Journal
06 Oct 2022 //
BUSINESSWIRE
Octapharma USA to Present Clinical Overview of Dermatomyositis
07 Sep 2022 //
BUSINESSWIRE
Octapharma Adopts Automated Application System from Schreiner MediPharm
18 Aug 2022 //
CONTRACTPHARMA
Octapharma shares new data at ISTH 2022 in its mission to meet the challenges
04 Jul 2022 //
PRNEWSWIRE
Octapharma to address unmet needs in von Willebrand disease as a proud sponsor
25 Apr 2022 //
PRNEWSWIRE
Octapharma’s fibryga & Octaplas Become Important COVID Replacement Therapies
24 Jan 2022 //
BUSINESSWIRE
FDA Approves Octapharma’s cutaquig 16.5% for Pediatric PI Patients
07 Dec 2021 //
BUSINESSWIRE
Octagam® 10% Receives 7 Years of Market Exclusivity for Dermatomyositis
30 Aug 2021 //
BUSINESSWIRE
FDA Approves Octapharma’s Octagam® 10% for Adult Dermatomyositis
20 Jul 2021 //
BUSINESSWIRE
Octapharma to present new clinical & scientific findings of haematology
06 Jul 2021 //
PHARMABIZ
Octapharma to present continued dedication to improving lives with hemophilia
06 Jul 2021 //
PR NEWSWIRE
FDA Approvals Strengthen Octapharma USA Pediatric Critical Care Product
29 Mar 2021 //
BUSINESSWIRE
Octapharma Final data from the NuProtect study published on the of Nuwiq®
22 Feb 2021 //
BIOSPACE
Akron Biotech, Octapharma enter Human AB Serum global production deal
21 Jan 2021 //
PHARMACEUTICAL-TECHNOLOGY
Akron Biotech Signs Exclusive Global Agreement with Octapharma
20 Jan 2021 //
PRESS RELEASE
Octapharma to Demonstrate Ongoing Commitment to Improving the Long-term Health
11 Jan 2021 //
BUSINESSWIRE
Octapharma to Demonstrate Ongoing Commitment to Improving
11 Jan 2021 //
BUSINESSWIRE
FDA Extends Shelf Life of Octapharma’s cutaquig® 16.5% for Adult PI Patients
05 Jan 2021 //
BUSINESSWIRE
Octapharma USA Presents Research on Congenital & Acquired Bleeding
03 Dec 2020 //
BUSINESSWIRE
Octapharma USA Presents Results of Investigational Use of Octagam®
02 Dec 2020 //
BUSINESSWIRE
Octapharma USA presents bleeding disorders research at virtual ASH
01 Dec 2020 //
EUREKALERT
Octapharma USA Presents Bleeding Disorders Research
01 Dec 2020 //
BUSINESSWIRE
Octapharma announces FDA approval of updated NUWIQ®
19 Oct 2020 //
BUSINESSWIRE
Patient recruitment start for the international PRO-SID study evaluating Panzyga
17 Sep 2020 //
OCTAPHARMA
Patient recruitment starts for study evaluating Panzyga for primary prophylaxis
17 Sep 2020 //
BIOSPACE
Patient recruitment starts for the international PRO-SID evaluating Panzyga
16 Sep 2020 //
BUSINESSWIRE
Octapharma USA Announces Medicare Part B Approval of cutaquig
15 Sep 2020 //
PRESS RELEASE
Intravenous Immunoglobulin Reduces Respiratory Morbidity in COVID-19
09 Sep 2020 //
BIOSPACE
Octapharma initiates Phase III trial of Panzyga in PANS patients
04 Sep 2020 //
CLINICALTRIALSARENA
Octapharma Launches Phase 3 for Pediatric Acute-onset Neuropsychiatric Syndrome
03 Sep 2020 //
BUSINESSWIRE
Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19
15 Jul 2020 //
BUSINESSLWIRE
Octapharma USA Extends Funding for COVID-19 Study Following Positive Data
02 Jun 2020 //
BUSINESSWIRE
Octapharma to study Octagam for severe Covid-19 in US
21 May 2020 //
CLINICALTRIALSARENA
FDA Approves Octapharma USA Investigational New Drug Application
20 May 2020 //
BUSINESSWIRE
FDA Approves Octapharma USA INDA for Severe COVID-19 Patients
20 May 2020 //
BIOSPACE
New COVID-19 Clinical Trial Supported by Octapharma USA
16 Apr 2020 //
BUSINESSWIRE
Global Plasma Collaborate to Accelerate Development of Potential COVID-19
06 Apr 2020 //
PRESS RELEASE
FDA Approves Octapharma’s WILATE® for Hemophilia A in Adult patients
09 Oct 2019 //
BUSINESS WIRE
Octapharma present data on the benefits of Nuwiq® in patients with haemophilia A
29 May 2018 //
BUSINESSWIRE
Octapharma Canada Inc Recalls Octagam
30 Jan 2017 //
HEALTH CANADA
December CHMP decisions bring year’s total approvals to 81
03 Jan 2017 //
PHARMATIMES
Cannabis Testing Companies Get Green Light From BofA Merrill Lynch
21 Dec 2015 //
IN-PHARMATECHNOLOGIST
Octapharma AG Invests €80 Million to Acquire an Exclusive Worldwide License
09 Oct 2015 //
THE FINANCIAL EXPRESS
